Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local methylprednisolone injection plus systemic therapy for idiopathic granulomatous mastitis
IRCT20200608047694N2Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methylprednisolone in Granulomatous lobular mastitis (GLM) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Primary efficacy endpoint. Started Dec 2024; status: completed.
02
Drugs
methylprednisolone
03
Conditions
Granulomatous lobular mastitis (GLM)
Beyond the preview
Go deeper on IRCT20200608047694N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200608047694N2.